Pharmaceutical compositions comprising silicones and two solubilized active principles
Topically applicable, anhydrous and physically/chemically stable pharmaceutical compositions useful for the treatment of disorders of the skin, notably psoriasis, contain a silicone agent; a therapeutically effect amount of a compound A, which is vitamin D or derivative thereof, solubilized in a solvent therefor; and a therapeutically effective amount of a compound B, which is the corticosteroids, also solubilized in a solvent therefor.
1. A topically applicable pharmaceutical composition for use in the treatment of psoriasis, consisting essentially of:
(a) cyclomethicone 5/dimethicone crosspolymer, in an amount of from 74.9347 to about 78.9347% by weight relative to the total weight of the composition;
(b) calcitriol, in an amount of 0.0003% by weight relative to the total weight of the composition;
(c) clobetasol 17-propionate, in an amount of 0.025% by weight relative to the total weight of the composition;
(d) at least two solvents in which (b) and (c) are solubilized which are at least absolute ethanol and cyclopentasiloxane;
(e) an oily additive selected from the group consisting of isopropyl palmitate, dicapryl ether and dimethicone; and
(f) butylated hydroxytoluene;
said composition having a zero water content and being physically stable for at least one month at 4° C. and 40° C.
2. A regime or regimen for the treatment of psoriasis, comprising topically applying onto the affected area of the skin of an individual afflicted with psoriasis, an anti-psoriasis effective amount of a composition as defined in claim 1 .